The path followed by a case of HER2-negative HR-positive breast cancer from the moment of diagnosis to the present time: clinical caseIovanovici, LauraOncolog-Hematolog
2. Is there room for targeting HER2-negative tumors with low HER2 expression (meaning cases with IHC score 1+ or 2+ not amplified by FISH)? Starting from the first question, the level of HER2 expression evaluated either by IHC or mRNA has been shown to be prognostic for metastatic BC pat...
The RNA4 classifier assigns low risk (0 votes) if ESR1-positive and ERBB2-low status, and AURKA expression value below the PGR-dependent cut point; and high risk (2 risk votes) if ESR1-negative, ERBB2-positive, or AURKA expression value above the PGR-dependent cut point. However, samples...
Patients were stratified at randomization based on 3 factors, including tumor progression to metastatic phase in 2 or fewer years or more than 2 years after primary diagnosis, centrally determined estrogen receptor and progesterone receptor status (≥1 positive or both negative), and type of taxane...
In the past decades, transcriptomic studies have revolutionized cancer treatment and diagnosis. However, tumor sequencing strategies typically result in loss of spatial information, critical to understand cell interactions and their functional relevance.
To test the hypothesis that tissues predicted to be ER-positive or negative may have similar visual characteristics, we embedded fingerprints from whole-slides into a low dimensional space using a fast implementation of the tSNE algorithm. tSNE is an unsupervised non-linear technique which compresses...
Patients enrolled in the CALGB 40601 trial were significantly younger, more likely to be premenopausal, and at a more advanced clinical stage at diagnosis than those enrolled in the nonchemotherapy PAMELA trial. There were no significant differences between the trials in the hormone receptor status ...
these patients had a PFS comparable to patients with HER2-positive disease at the outset. These results illustrate that re-biopsies could be considered on the development of disease relapse or progression in HER2-negative tumours, as it could dictate eligibility for HER2-targeted therapies. Conversely...
NST is an opportunity for HER2-positive cancers. In this series of over a hundred HER2-positive and non-metastatic patients, a STARD3-negative score was associated with the absence of pathological complete response. This study suggests that determining STARD3 overexpression status on initial biopsies...
(HER2) negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The FDA grants priority review for th...